BLRX - BioLineRx Ltd Stock Trading

BioLineRx Reports Second Quarter 2021 Financial Results and Provides Corporate Update - Company actively preparing for an NDA submission for Motixafortide in stem cell mobilization targeted for H1 2022 - - Cash and cash equivalents of $66 million at June 30, 2021 - - Man...

BioLineRx to Report Second Quarter 2021 Results on August 18, 2021 Management to hold a conference call at 10:00 a.m. EDT PR Newswire TEL AVIV, Israel , Aug. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinical-stage bioph...

In recent years, biomedical research on topics surrounding longevity and aging has gained a tremendous amount of traction. The biotech industry as well as major pharmaceutical companies, have also jumped onto the bandwagon of discovering ways to alter and reverse the aging process. Currently, ...